Actively Recruiting
Evaluation of Oral CSCJC3456 Tablets for Safety and Preliminary Efficacy in Patients with Advanced Malignant Solid Tumors Using Dose Escalation and Cohort Expansion
Led by Changshan ConjuChem BioPharmaceutical Research and Development (Hebei) Co., Ltd. · Updated on 2026-09-21
102
Participants Needed
2
Research Sites
52 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating CSCJC3456, a new multi-target tyrosine kinase inhibitor, in patients with advanced malignant solid tumors. This first-in-human, open-label phase I study aims to assess the safety, tolerability, how the drug acts in the body, and preliminary effectiveness. The study is divided into two parts Phase Ia for dose escalation and Phase Ib for cohort expansion focusing on selected tumor types. In Phase Ia, participants receive single or multiple doses of CSCJC3456 tablets orally, with doses ranging from 5 to 540 mg per day, given once or twice daily either continuously or intermittently in 21- or 28-day cycles. Phase Ib uses the recommended dose from Phase Ia and involves patients with specific tumor types, including hepatocellular carcinoma, colorectal cancer, gastric cancer, and endometrial cancer, with selection based on genetic markers and response data. Participants will be closely monitored throughout the study, which includes assessments of dose-limiting toxicity and maximum tolerated dose in Phase Ia, and objective response rates in Phase Ib. Safety and toxicity are evaluated from enrollment until 28 days after the last dose. Pharmacokinetic and pharmacodynamic measurements are taken during treatment cycles. The trial aims to follow participants for up to two years to observe treatment effects and survival outcomes.
CONDITIONS
Brief Title
A Study of CSCJC3456 in Patients With Advanced Malignant Tumors
Research Team
N
Ning Li, M.D.
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here